Survival of Ovarian Cancer Patients Increased by 70% After the First-Ever Clinical Trial Using Tocotrienols


A recent study that was conducted at Vejle Hospital provides evidence of the benefits of delta-Tocotrienols for cancer patients.  The results of the study were published in the journal named Pharmacological Research.  The results of the first-ever open-trial clinical test suggest that delta-tocotrienols by American River Nutrition when combined with bevacizumab, tends to have additive effects in cases of ovarian cancer.  This turns out to be the first-ever clinical trial that makes use of tocotrienols in the patients having ovarian cancer.

In the given study, 23 patients with advanced-stage ovarian cancer were sampled.  In these patients, tocotrienols was administered at 300mg dosage at least 3 times a day.  This was given in combination to bevacizumab at 10mg/kg to the patients every 3 weeks.  After this, patient disease stabilization was achieved higher at around 70 percent with an extended survival rate.  This rate had doubled approximately.


Jonathan Lizotte –Board President and Health Co-founder, says, “The thing that is the most exciting about this study is that it is able to provide support to the growing concern of tocotrienols being life-changing.  I would like to thank the Danish Government as well as Dr. Jakobsen along with his group for the given novel and open-minded approach in making use of vitamin in combination with standard therapy.  It is the given forward thinking that aims at bringing about a major breakthrough for the treatment as well as prevention of cancer along with other life-threatening diseases.”

Ovarian cancer turns out to rank 5th in being one of the most common causes of deaths due to cancer in women all around the world.  As per the reports of American Cancer Society, around 22,240 women in the United States of America received the new diagnosis for ovarian cancer, while around 14,070 patients died due to the same in the year 2018.  As ovarian cancer cannot be easily diagnosed until it reaches the advanced stage, the 5-year survival rate for this type of cancer turns out to be only around 47 percent.  Patients having an advanced form of ovarian cancer usually face the recurrence of the disease after receiving primary treatment.

In the given scenario, such clinical trials might appear hopeful in the prevention and treatment of ovarian cancer across the world.